Mirum Pharmaceuticals reports Q4 revenue $148.93M, consensus $141.81M

Reports Q4 net loss ($5.73M) vs. ($23.79M) last year. “2025 was a year of meaningful progress and execution for Mirum, setting the stage for a pivotal 2026,” said Chris Peetz, CEO of Mirum. “With the recent addition of brelovitug in HDV, we now expect four potentially registrational readouts over the next 18 months, beginning with topline results from the VISTAS study in PSC in the second quarter. This catalyst-rich period, combined with continued commercial performance and financial discipline, positions us well to deliver for shareholders and patients.”